CHECKIT
John Wilson
CEO
We have worked with Yellowstone Advisory for a number of years and they transformed our investor relations strategy which significantly increased the interest of our business to both institutional and retail investors. We have been impressed by their understanding of the smaller companies market and their results focussed approach to IR. I would recommend their services without hesitation.
EQUINITI
Guy Wakeley
CEO
Yellowstone Advisory provided valuable input into the interim results announcement and presentation, helping to ensure the investment messaging was consistent throughout the documents. Great relationships and credibility with investors enables them to solicit useful feedback which we have used in developing our future investor messaging.
.png){kind=small}
Oxford Biodynamics HY Results Webinar
Tue, 15 Jun
|Webinar
Jon Burrows, CEO presents the HY results which are released on 15 June and updates on current performance
Time & Location
15 Jun 2021, 16:00 – 17:00
Webinar
About the event
Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.